Stevens-Johnson syndrome associated with thalidomide treatment in HIV infection

AIDS Reader

Volumn 18, Issue 10, 2008, Pages 519-520

  Tebruegge, Marc ^a,b,c   Pantazidou, Anastasia ^a  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

Author keywords

Adolescence; HIV AIDS; Stevens johnson syndrome; Thalidomide; Toxic epidermal necrolysis

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; IBUPROFEN; IMMUNOGLOBULIN; INFUSION FLUID; LOPINAVIR PLUS RITONAVIR; MORPHINE; PARACETAMOL; THALIDOMIDE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADOLESCENT; ARTICLE; CASE REPORT; CD4 LYMPHOCYTE COUNT; CLINICAL EXAMINATION; CLINICAL FEATURE; DISEASE COURSE; DRUG WITHDRAWAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MOUTH ULCER; PAIN; RECURRENT DISEASE; STEVENS JOHNSON SYNDROME; CHEMICALLY INDUCED DISORDER; TOXIC EPIDERMAL NECROLYSIS;

ADOLESCENT; ANTI-HIV AGENTS; EPIDERMAL NECROLYSIS, TOXIC; HIV INFECTIONS; HUMANS; MALE; ORAL ULCER; STEVENS-JOHNSON SYNDROME; THALIDOMIDE;

EID: 55449104900     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Chan HL, Stern RS, Amdt KA, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol. 1990;126:43-47.
2. French LE. Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. Allergol Int. 2006;55:9-16.
3. Fagot JR Mockenhaupt M, Bouwes-Bavinck JN, et al; EuroSCAR Study Group. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS. 2001;15:1843-1848.
4. Pollard RB, Robinson P, Dransfield K. Safety profile of nevirapine, a nonnucleo-side reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther. 1998;20:1071-1092.
5. Barner A, Myers M. Nevirapine and rashes. Lancet, 1998;351:1133.
6. Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008;128:35-44.
7. Jacobson JM. Thalidomide: a remarkable comeback. Expert Opin Pharmacolher. 2000;1:849-863.
8. Wolkenstein P, Latarjet J, Roujeau JC, et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet. 1998;352:1586-1589.
9. Clark TE, Edom N, Larson J, Ljndsey LJ, Thalomid(Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing. Drug Saf. 2001;24:87-117.